GSK announced on Wednesday that it had signed a licensing agreement with the Chinese biopharmaceutical company Hansoh for the development of an antibody-drug conjugate.

Under the terms of this agreement, GSK will have an exclusive option to pursue the development of HS-20093, as well as its commercialization outside China, Hong Kong, Macao and Taiwan.

GSK, which notes that HS-20093 is currently undergoing Phase I and II clinical trials in China for the treatment of solid tumors, plans to launch a study outside China next year.

In return, the company has agreed to pay Hansoh an upfront payment of $8 million, to which could be added more than $1.5 billion in milestone payments in the event of the project's success, in addition to possible royalties on future sales of the drug.

Copyright (c) 2023 CercleFinance.com. All rights reserved.